TAS niet voor vergoeding medicijn Alimta

25-05-2005

Minister Hoogervorst is niet van plan om asbestslachtoffers een voorschot te geven voor het nieuwe, relatief dure astbestmedicijn Alimta. Volgens hem is de Regeling tegemoetkoming asbestslachtoffers (TAS) hier niet geschikt voor. Dat schrijft de minister vrijdag in antwoord op vragen van Tweede-Kamerlid De Wit.

Bron: Telegraaf.nl , 29 april.

Meer

http://www.telegraaf.nl/…

Verlies voor ABB door asbestclaims

25-05-2005

Het Zweeds-Zwitserse concern ABB heeft over 2004 een verlies geleden van $ 35 mln in plaats van een winst van $ 201 mln, die het eerder heeft gemeld. De herziening van het resultaat is het gevolg van een extra storting in een fonds dat is opgericht om slachtoffers van asbest tegemoet te komen. In maart verklaarde ABB $ 232 mln extra inzake de asbestclaims te betalen.

Bron: ANP/Het Financieele Dagblad, 23 april.

Giftige sloopschepen

25-05-2005

Het slopen van schepen gebeurt in ontwikkelingslanden. Prachtige stranden in India, Bangladesh, Pakistan en Turkije zijn veranderd in scheepskerkhoven. Als ze uit de vaart zijn, worden schepen verkocht vanwege het waardevolle staal. Maar in oude schepen zitten veel gevaarlijke stoffen, zoals asbest, loodverf en PCB s. Als de schepen worden gesloopt komen deze stoffen vrij. Ze komen terecht in het milieu en in de lichamen van de arbeiders. Greenpeace roept op tot actie.Bron: Greenpeace.nl , 1 april.

Meer http://www.greenpeace.nl/campaigns/giftige-stoffen-2/giftige-sloopschepen

Malafide slopers kunnen ongestoord hun gang gaan

25-05-2005

Malafide aannemers die illegaal asbest verwijderen kunnen ongestoord hun gang gaan doordat gemeenten en inspecties geen toezicht houden. Sloopprojecten waarvoor geen vergunning wordt aangevraagd, worden niet gecontroleerd. In een vorig jaar verschenen rapport spreekt de Vrom-inspectie over een aanzienlijk handhavingstekort.

Bron: Apeldoornse Courant, 7 april.

Asbestslachtoffers hebben recht op dure medicijnen

27-04-2005

Alle mesothelioompatiënten die ziek zijn geworden door het inademen van asbest, hebben recht op het nieuwe geneesmiddel Alimta.

Het ministerie van Volksgezondheid, Welzijn en Sport heeft de FNV verzekerd dat deze patiënten nooit om niet-medische redenen het geneesmiddel geweigerd mag worden. Mocht dit wel gebeuren, dan kan de patiënt met zijn zorgverzekeraar naar het betreffende ziekenhuis stappen.

Bron: FNV e-Magazine, 27 april 2005, jaargang 6, nummer 17.

Meer http://www.fnv.nl/nieuws/renderer.do/clearState/true/menuId/9028/returnPage/8886/

Australië: doorbraak in screening van mesothelioom

25-03-2005

Australische onderzoekers hebben een bloedtest ontwikkeld die kan helpen bij het opsporen van mesothelioom. De niet invasieve test, Mesomark genaamd, werd ontwikkeld door onderzoekers van de Universiteit van West Australië. In Australië krijgen ongeveer 700 mensen per jaar deze ziekte.

Bron: The Advertiser, 20 april / The West Australian, 19 april.

The Advertiser

April 20, 2005 Wednesday

HEADLINE: Breakthrough

AUSTRALIAN researchers have developed a world-first blood test which could help people worldwide in the early detection of mesothelioma, a deadly asbestos-related cancer of the lung lining. The non-invasive blood test developed by University of Western Australia Professor Bruce Robinson and researchers is a breakthrough in the early detection of the disease. About 700 people each year are diagnosed with the disease in Australia, which has the highest reported incidence in the world.

The West Australian (Perth)

April 19, 2005 Tuesday

HEADLINE: Test offers hope on mesothelioma

Rockingham man David Saw believes a new blood test for mesothelioma, which is being launched today, could have saved him a three-day hospital visit and a lot of trauma.

Mr Saw went to his doctor last year believing he had pulled a muscle.

He was suffering chest pain and shortness of breath.

After a CAT scan and biopsy, it was revealed the 49-year-old had contracted the deadly lung cancer from working with asbestos as a young man.

“A test would have been a lot easier, I ended up in hospital and they had to cut me open,” he said.

The test, called MESOMARK, will be available from general practitioners or specialists who can order it from a pathology provider.

The head of the mesothelioma research team at Sir Charles Gairdner Hospital which developed the test, Professor Bruce Robinson, said it would not only help in diagnoses of the disease, but also in treatment.

“Until now you could only gauge whether treatment was working effectively by doing a CAT scan, and they’re difficult to do. With this test, we can gauge treatment and also diagnose it at an earlier stage,” Professor Robinson said. Biopsy would be needed to confirm diagnosis.

The blood test measures levels of a substance called soluble mesothelin-related peptide, a distinctive biomarker released by mesothelioma cells.

About 700 Australians are diagnosed with the disease every year and WA has the highest rate of mesothelioma in the world.

Asbestos Diseases Society of Australia president Robert Vojakovic said the test could help the possible 6000 people who were children in Wittenoom when the town still had an active blue asbestos mine.

"Pleurale plaques" voorspelt asbestgerelateerde longkanker

15-03-2005

Bij mannen die geen asbestose (“stoflongen” door asbest) hebben komt asbestgerelateerde longkanker vaker voor dan was verwacht. “Pleurale plaques” (een goedaardige verdikking van het borstvlies) is een belangrijke voorspeller van asbestgerelateerde longkanker. Deze nieuwe inzichten komen uit een onderzoek van meer dan 10 jaar onder 4000 Amerikaanse mannen die aan asbest blootgesteld zijn geweest.
Increased lung cancer among asbestos workers with no evidence of asbestosis

Below, details of a new paper on asbestos and lung cancer, forwarded by Frank Mirer, director of health and safety at the US autoworkers’ union UAW.

The paper looks important for two reasons – firstly because of the lung cancer without asbestosis finding – in some jurisdictions official workers’ compensation schemes only pay benefits to lung cancer sufferers who also have asbestosis.

Secondly, the paper is valuable because it establishes the importance of pleural plaques as a predicator of lung cancer. Insurers and employers in the UK, USA and elsewhere are at this moment trying to play down the significance of the association between pleural plaques and asbestos.

Their motive is to reduce their compensation liabilities. One consequence of this might be a lower likelihood of diagnosis of pleural plaques (many of the health checks are the result of compensation inquiries), so we could lose our early warning system or “sentinel health event” for an enormous lung cancer risk. In the UK at the moment there are several thousand asbestos related lung cancers ever year – the combined annual death toll for asbestos related lung cancers and mesothelioma is expect to reach 10,000 within 20 years.

Yours, Rory

Rory O’Neill

International Federation of Journalists

Increased lung cancer among asbestos workers with no evidence of asbestosis

A very important study giving quantitative measures of risks of asbestos exposure was just published. The study is an important data source for evaluating medical criteria for compensation of asbestos exposed workers, now being discussed in Congress.

The project was a chemoprevention test whether Vitamin A – an antioxidant – protected against future effects of past asbestos exposure. The investigators had enrolled over 4,000 asbestos workers and followed them for over a decade. Recruitment must have been a huge task The chemoprevention study was terminated because Vitamin A increased the risk of lung cancer.

The study confirmed excessive rates of lung cancer among men with radiographic asbestosis, but also among workers with no evidence of asbestosis. Among workers with no evidence of asbestosis at baseline, men with more than 40 years’ exposure in high-risk trades had a risk approximately fivefold higher than men with 5-10 years. Pleural plaques on the baseline x-ray and abnormal baseline flow rate were strong independent predictors of subsequent lung cancer.

Hopefully, people with access to the full text of this study will comment further.

American Journal of Epidemiology 2005 161(3):260-270.

Predictors of Lung Cancer among Asbestos-exposed Men in the µ-Carotene and

Retinol Efficacy Trial

Mark R. Cullen1 , Matt J. Barnett2, John R. Balmes3, Brenda Cartmel1, Carrie

A. Redlich1, Carl A. Brodkin4, Scott Barnhart4, Linda Rosenstock5, Gary E.

Goodman2,6, Sam P. Hammar7, Mark D. Thornquist2 and Gilbert S. Omenn8,9

Despite numerous published studies, debate continues regarding the risk of developing lung cancer among men exposed occupationally to asbestos, particularly those without radiographic or functional evidence of asbestosis. The µ-Carotene and Retinol Efficacy Trial (CARET), a study of vitamin supplementation for chemoprevention of lung cancer, has followed 4,060 heavily exposed US men for 9-17 years. Lung cancer incidence for 1989-2002 was analyzed using a stratified proportional hazards model. The study confirmed excessive rates of lung cancer among men with radiographic asbestosis. Comparison of study arms revealed a strong, unanticipated synergy between radiographic profusion category and the active intervention. In the large subgroup of men with normal lung parenchyma on chest radiograph at baseline, there was evidence of exposure-related lung cancer risk: Men with more than 40 years’ exposure in high-risk trades had a risk approximately fivefold higher than men with 5-10 years, after adjustment for covariates. The effect in these men was independent of study intervention arm, but pleural plaques on the baseline radiograph and abnormal baseline flow rate were strong independent predictors of subsequent lung cancer. Residual confounding by subclinical asbestosis, exposure to unmeasured lung carcinogens, or differences in smoking are unlikely to explain these observations better than a carcinogenic effect of asbestos per se.

Asbestblootstelling en Retroperitoneale Fibrose (RPF)

15-03-2005

Dit artikel in de Lancet beschrijft de hypothese dat asbestblootstelling een oorzaak is van bindweefseltoename rond organen achter het buikvlies. De onderzoekers concluderen dat dat beroepsmatige asbestblootstelling een belangrijke oorzaak van deze aandoening is. RPF zou daarom als een beroepsziekte moeten worden gezien.

Bron: the Lancet, mei 2004.
Asbestos exposure as a risk factor for retroperitoneal fibrosis

Summary

Background Retroperitoneal fibrosis (RPF) is an uncommon disease with unknown causation in most cases. The pathognomonic finding is a fibrous mass covering the abdominal aorta and the ureters. Our aim was to clarify the possible role of asbestos exposure in the development of RPF. The hypothesis was based on the ability of asbestos to cause fibrosis in pulmonary and pleural tissue. Methods We undertook a case-control study of 43 patients with the disease (86% of eligible cases) treated in three university hospital districts of Finland in 1990-2001. For every patient, five population-based controls were selected, matched by age, sex, and central hospital district. We assessed asbestos exposure and medical history using a postal questionnaire and a personal interview. Of the 215 eligible controls, 179 (83%) participated in the study. Findings The age-standardised incidence of RPF was 0-10 (95% CI 0-07-0-14) per 100 000 person-years. The disease was strongly associated with asbestos exposure. The odds ratio (OR) was 5-54 (1-64-18-65) for less than 10 fibre-years of asbestos exposure and 8-84 (2-03-38-50) for 10 or more fibre-years, the attributable fraction being 82% and 89%, respectively. Other risk factors were previous use of ergot derivates (OR 9-92 [1-63-60-26]), abdominal aortic aneurysm (OR 6-73 [0-81-56-08]), and smoking for more than 20 pack-years (OR 4-73 [1-28-17-41]). Interpretation Our results show that occupational asbestos exposure is an important causal factor for RPF. For patients with work-related asbestos exposure, RPF should be considered an occupational disease.

Toomas Uibu, Panu Oksa, Anssi Auvinen, Eero Honkanen, Kaj Metsärinne, Heikki Saha, Jukka Uitti, Pekka Roto. Lancet 2004. 363: 1422-26.

Buikvlieskanker door het eten van met asbest besmet voedsel

15-03-2005

Dit onderzoek beschrijft het geval van een 76 jarige vrouw met buikvlieskanker door het eten van met asbest besmet voedsel. Zij vertelde dat ze gewend was groenten te koken in regenwater dat verzameld werd uit een dakgoot van asbestgolfplaat.

Bron: Van Kesteren et al. (2004). International Journal of Gynecological Cancer.
Malignant peritoneal mesothelioma in a 76-year-old woman with a history of asbestos fiber ingestion

Author(s): P. Van Kesteren . J. Bulten . C. Schijf . H. Boonstra . L. Massuger

Source: International Journal of Gynecological Cancer Volume: 14 Number: 1 Page: 162 — 165

DOI: 10.1111/j.1048-891x.2004.14149.x

Publisher: Blackwell Publishing

Abstract: Abstract. van Kesteren P, Bulten J, Schijf C, Boonstra H, Massuger L. Malignant peritoneal mesothelioma in a 76-year-old woman with a history of asbestos fiber ingestion.

We report on a woman with malignant mesothelioma of the peritoneum. This is the first report of a subject with this disease who revealed a history of asbestos ingestion by asbestos-contaminated food. She presented with episodes of sweating and fever, ascites, and weight loss. At laparotomy, small tumor deposits were noted on the peritoneum. The omental cake was removed, together with the uterus, ovaries, and tubes which were all macroscopically normal. The diagnosis was established by immunohistochemistry and electron microscopy. Postoperatively, her complaints of fever and sweating disappeared. She refused further chemotherapy. After questioning her for asbestos exposure, she told us that, years ago, she used to prepare vegetables for cooking in rain water collected from a roof made of asbestos.

Aantal asbestzaken Philips flink toegenomen in 2004

15-03-2005

Philips heeft het aantal asbestzaken in de Verenigde Staten vorig jaar met 170% zien toenemen tot 2.909, en het aantal eisers met 118% tot 6.028. Dat blijkt uit het jaarverslag 2004, dat het elektronicaconcern dinsdag heeft gepubliceerd. De zaken zouden verband houden met een al in 1981 verkocht chemiebedrijf, dat in het kankerverwekkende asbest handelde. Bron: Betten Beursmedia News, 22/02/2005 15:57.

Meer http://www.rabobank.nl/info/execute/nieuws/artikel?node_id=234955&articleId=312658